| Anti-tumour effects of triple therapy with octreotide, galanin and serotonin in comparison with those of 5-fluorouracil/leukovorin on human colon cancer. | |
| | |
MedLine Citation:
|
PMID: 16010424 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Human colon cancer cells were injected subcutaneous in nude mice. After 8 days the animals were divided in two groups, the first group received triple therapy with octreotide, galanin and serotonin (40 microg/kg body weight/day) through an ALZET osmotic pump implanted intraperitoneally (i.p.) for 14 days, followed by 5 days of subcutaneous injections (200 microg/kg body weight/ day). The second group was injected i.p. for 5 days with 5-fluorouracil/leukovorin (5-FU/LV) at concentrations of 4 mg and 2 mg/kg body weight, respectively. After 9 days without any treatment, the mice received i.p. injection with 5-FU/LV (20 mg and 10 mg/kg body weight/day, respectively) for another 5 days. The volume and weight of the tumours were measured at the end of the experiment. Apoptosis, proliferation, blood vessels, epidermal growth factor (EGF) and vascular endothelial cell growth factor (VEGF) were detected with immunocytochemistry. Apoptosis was also detected using the TUNEL-method. Quantification was performed using computed image analysis. There was no statistical significance between tumours treated with 5-FU/LV or triple therapy regarding the volume and weights of the tumours, apoptotic, proliferation, VEGF indces and the density of tumour blood vessels. The EGF labelling index was, however significantly lower in the tumours treated with triple therapy than those treated with 5-FU/LV. In conclusion, treatment with triple therapy using octreotide, galanin and serotonin appear to be comparable with 5-FU/LV that is the standard chemotherapeutic agent for colorectal cancer. |
| | |
Authors:
|
Veronica Tjomsland; Magdy El-Salhy |
Related Documents
:
|
8616854 - Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induc... 22374154 - Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ran... 22699924 - Diuretic dosing in acute decompensated heart failure: lessons from dose. 22530664 - Rational administration schedule for high-dose mtx in patients with primary cns lymphoma. 6756934 - Variance comparison as a tool in clinical pharmacology: an example with two loop diuret... 10779464 - Endovascular irradiation from beta-particle-emitting gold stents results in increased n... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: International journal of oncology Volume: 27 ISSN: 1019-6439 ISO Abbreviation: Int. J. Oncol. Publication Date: 2005 Aug |
Date Detail:
|
Created Date: 2005-07-12 Completed Date: 2005-12-23 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9306042 Medline TA: Int J Oncol Country: Greece |
Other Details:
|
Languages: eng Pagination: 427-32 Citation Subset: IM |
Affiliation:
|
Division of Gastroenterology and Hepatology, Department of Molecular and Clinical Medicine, Faculty of Health Sciences, University Hospital, Linköping, Sweden. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antigens, CD31 / analysis Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Apoptosis / drug effects Body Weight / drug effects Cell Line, Tumor Cell Proliferation / drug effects Colonic Neoplasms / drug therapy*, metabolism, pathology Epidermal Growth Factor / analysis Fluorouracil / administration & dosage Galanin / administration & dosage Humans Immunohistochemistry In Situ Nick-End Labeling Leucovorin / administration & dosage Mice Mice, Nude Neovascularization, Pathologic / metabolism, pathology, prevention & control Octreotide / administration & dosage Poly(ADP-ribose) Polymerases / analysis Serotonin / administration & dosage Vascular Endothelial Growth Factor A / analysis Xenograft Model Antitumor Assays / methods* |
| Chemical | |
Reg. No./Substance:
|
0/Antigens, CD31; 0/Vascular Endothelial Growth Factor A; 50-67-9/Serotonin; 51-21-8/Fluorouracil; 58-05-9/Leucovorin; 62229-50-9/Epidermal Growth Factor; 83150-76-9/Octreotide; 88813-36-9/Galanin; EC 2.4.2.30/Poly(ADP-ribose) Polymerases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Genomic screens for genes upregulated by demethylation in colorectal cancer: possible usefulness for...
Next Document: Antitumor activity of cationic liposome-mediated Bax gene transfer in osteosarcoma cells: induction ...